Economic Analyses of Rare Kidney Diseases
Author Information
Author(s): Angell Blake, Wang Siyuan, Gadsden Thomas, Moorthy Monica, Malik Charu, Barratt Jonathan, Devuyst Olivier, Ulasi Ifeoma I., Gale Daniel P., Sengupta Agnivo, Palagyi Anna, Jha Vivekanand, Jan Stephen
Primary Institution: The George Institute for Global Health, University of New South Wales, Sydney, Australia
Hypothesis
The study aims to investigate the economic burden and cost-effectiveness evidence base for rare kidney diseases (RKDs).
Conclusion
There are significant gaps in the economic evidence base for RKDs, indicating a need for innovation in investment cases for treatments.
Supporting Evidence
- 161 studies were included in the review, highlighting the economic burden of RKDs.
- Most studies focused on renal cell carcinomas and systemic lupus erythematosus.
- Limited evidence was found from lower-income settings.
- Many studies did not consider broader economic impacts on patients.
Takeaway
Rare kidney diseases cost a lot of money to treat, and we don't know enough about their economic impact, which makes it hard to decide how to spend money on treatments.
Methodology
A systematic scoping review was conducted to identify economic evaluations, health technology assessments, and cost-of-illness studies related to RKDs published since 2012.
Potential Biases
Most included studies were funded by pharmaceutical companies, which may skew the focus away from nonpharmaceutical interventions.
Limitations
The review faced challenges due to the heterogeneity of included studies and inconsistent reporting of costs.
Participant Demographics
The majority of studies originated from high-income nations, particularly the USA, with limited evidence from low- and middle-income countries.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website